Advanced

Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia

Mattsson, Niklas LU ; Grigoriou, Sotirios and Zetterberg, Henrik LU (2018) p.221-252
Abstract

Fluid biomarkers, including cerebrospinal fluid (CSF) biomarkers and blood-based biomarkers, may reflect different pathological processes in Alzheimer’s disease (AD) and frontotemporal dementia (FTD). The most used biomarkers are CSF β-amyloid42, total tau, phosphorylated tau, and neurofilament light, which have been studied for diagnosis, prognosis, and treatment follow-up and in relation to genetics and neuroimaging. These biomarkers are now increasingly used in research, drug development, and clinical settings to increase our understanding of AD and FTD and to improve patient management. Recent progress in stable, automated assays for CSF biomarkers and ultrasensitive assays for blood-based biomarkers and the incorporation of fluid... (More)

Fluid biomarkers, including cerebrospinal fluid (CSF) biomarkers and blood-based biomarkers, may reflect different pathological processes in Alzheimer’s disease (AD) and frontotemporal dementia (FTD). The most used biomarkers are CSF β-amyloid42, total tau, phosphorylated tau, and neurofilament light, which have been studied for diagnosis, prognosis, and treatment follow-up and in relation to genetics and neuroimaging. These biomarkers are now increasingly used in research, drug development, and clinical settings to increase our understanding of AD and FTD and to improve patient management. Recent progress in stable, automated assays for CSF biomarkers and ultrasensitive assays for blood-based biomarkers and the incorporation of fluid biomarkers in clinical practice and in clinical trials have accelerated the field. Key issues for further research include more extensive studies of the earliest stages of neurodegenerative diseases, better biomarkers for distinct proteinopathies, and the creation of universally accepted guidelines specifying the role of fluid biomarkers in relation to clinical measures and neuroimaging findings.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Chapter in Book/Report/Conference proceeding
publication status
published
subject
keywords
Alzheimer, Amyloid, Biomarker, Frontotemporal lobe dementia, Neurofilament, Tau
host publication
NeurodegeneratIve Diseases
pages
32 pages
publisher
Springer International Publishing AG
external identifiers
  • scopus:85046599056
ISBN
9783319729374
9783319729381
DOI
10.1007/978-3-319-72938-1_11
language
English
LU publication?
yes
id
32821e75-c204-42e9-8c62-c6984ecf7322
date added to LUP
2018-05-25 13:28:40
date last changed
2019-09-17 04:33:08
@inbook{32821e75-c204-42e9-8c62-c6984ecf7322,
  abstract     = {<p>Fluid biomarkers, including cerebrospinal fluid (CSF) biomarkers and blood-based biomarkers, may reflect different pathological processes in Alzheimer’s disease (AD) and frontotemporal dementia (FTD). The most used biomarkers are CSF β-amyloid42, total tau, phosphorylated tau, and neurofilament light, which have been studied for diagnosis, prognosis, and treatment follow-up and in relation to genetics and neuroimaging. These biomarkers are now increasingly used in research, drug development, and clinical settings to increase our understanding of AD and FTD and to improve patient management. Recent progress in stable, automated assays for CSF biomarkers and ultrasensitive assays for blood-based biomarkers and the incorporation of fluid biomarkers in clinical practice and in clinical trials have accelerated the field. Key issues for further research include more extensive studies of the earliest stages of neurodegenerative diseases, better biomarkers for distinct proteinopathies, and the creation of universally accepted guidelines specifying the role of fluid biomarkers in relation to clinical measures and neuroimaging findings.</p>},
  author       = {Mattsson, Niklas and Grigoriou, Sotirios and Zetterberg, Henrik},
  isbn         = {9783319729374},
  keyword      = {Alzheimer,Amyloid,Biomarker,Frontotemporal lobe dementia,Neurofilament,Tau},
  language     = {eng},
  month        = {01},
  pages        = {221--252},
  publisher    = {Springer International Publishing AG},
  title        = {Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia},
  url          = {http://dx.doi.org/10.1007/978-3-319-72938-1_11},
  year         = {2018},
}